MarketCapExport financials
Anavex Life Sciences Corp. (AVXL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Anavex Life Sciences Corp. AVXL
$ 1.1
-12.0%
Facebook
X
Telegram
Anavex Life Sciences Corp. Financial Statements 2025-2004 | AVXL
Annual Financial Statements Anavex Life Sciences Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
291 M | 953 M | 513 M | 914 M | 913 M | 349 M | 136 M | 107 M | 170 M | 104 M | 197 M | 6.79 M | 16.6 M | 28.5 M | 47.8 M | 301 M | - | - | - | - | - | - |
Shares |
85.3 M | 83.5 M | 79.8 M | 76.9 M | 69.8 M | 58.2 M | 48.9 M | 44.7 M | 40.8 M | 35.2 M | 18.6 M | 9.93 M | 7.98 M | 7.04 M | 6.29 M | 23.5 M | - | - | - | - | - | - |
Historical Prices |
3.41 | 11.4 | 6.43 | 11.9 | 13.1 | 6.28 | 2.86 | 1.85 | 2.83 | 4.5 | 3.59 | 0.696 | 1.36 | 2.88 | 6.76 | 12.8 | 10.4 | 19.6 | 15.2 | - | - | - |
Net Income |
-46.4 M | -43 M | -47.5 M | -48 M | -37.9 M | -26.3 M | -26.3 M | -17.5 M | -13.5 M | -14.7 M | -12.1 M | -11.4 M | -3.7 M | -8.3 M | -7.31 M | -8.78 M | -5.5 M | -5.35 M | -1.58 M | -25.5 K | -91.6 K | -14.4 K |
Operating Income |
-51.4 M | -52.9 M | -55.8 M | -51 M | -42 M | -31.1 M | - | - | - | - | - | -2.97 M | -2.14 M | -4.32 M | -6.18 M | -5.65 M | - | - | - | - | - | - |
Interest Expense |
4.68 M | 7.32 M | 6.52 M | 947 K | 26 K | 180 K | 207 K | 255 K | 88.1 K | 11.3 K | 71.8 K | 7.09 K | 51.3 K | 138 K | 90.2 K | 285 K | - | - | - | - | - | - |
EBITDA |
-51.4 M | -52.9 M | -55.8 M | -51 M | -42 M | -31.1 M | -28.9 M | -19.1 M | -15.6 M | -14.9 M | -7.11 M | -2.97 M | -2.13 M | -4.31 M | -6.18 M | -5.65 M | - | - | - | - | - | - |
Operating Expenses |
51.4 M | 52.9 M | 55.8 M | 51 M | 42 M | -31.1 M | 28.8 M | 19.2 M | 15.5 M | 14.9 M | 7.11 M | 2.97 M | 2.13 M | 4.32 M | 6.18 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
13.8 M | 11 M | 12 M | 13.1 M | 9.02 M | 5.86 M | 6.85 M | 5.99 M | 5.01 M | 8.33 M | 4.84 M | 2.24 M | 1.87 M | 1.55 M | 3.44 M | 39.7 K | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Anavex Life Sciences Corp.
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
85.4 B | 85.1 M | 84.8 M | -3.23 M | 84.5 M | 82.5 M | 82.1 M | 84.8 M | 84.8 M | 84.5 M | 82.5 M | 82.1 M | 82.1 M | 80.9 M | 78.3 M | 78 M | 77.9 M | 77.9 M | 77.2 M | 76 M | 75.9 M | 75.1 M | 68.6 M | 64.3 M | 62 M | 59.1 M | 64.3 M | 54.8 M | 47.7 M | 49.6 M | 54.8 M | 46.3 M | 44.4 M | 45.2 M | 46.3 M | 43.9 M | 40.3 M | 41.5 M | 41.2 M | 38.4 M | 35 M | 35.7 M | 35.2 M | 34 M | 15.4 M | 19.1 M | 34 M | 12.9 M | 38.2 M | 39.3 M | 51.6 M | 37.5 M | 30.2 M | 30.2 M | 37.5 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 27.2 M | 26.6 M | 26.6 M | 26.6 M |
Net Income |
-13.2 M | -11.2 M | -12.1 M | -16.1 M | -12.2 M | -10.5 M | -8.62 M | -12.1 M | - | -12.2 M | -10.5 M | -8.62 M | - | -11.3 M | -13.1 M | -13 M | -33.7 M | -12.4 M | -10.4 M | -10.9 M | -26.2 M | -10.2 M | -8.16 M | -7.86 M | -20.3 M | -6.49 M | -7.86 M | -6.59 M | -20.7 M | -6.52 M | -6.59 M | -6.92 M | -11.7 M | -2.85 M | -7.33 M | -4.06 M | -8.31 M | -3.61 M | -4.06 M | -3.15 M | -8.23 M | -2.24 M | -3.15 M | -3.95 M | -6.75 M | -4.24 M | -3.95 M | -787 K | -1.67 M | -1.01 M | -787 K | 359 K | -712 K | -3.7 M | 359 K | -454 K | -8.3 M | -8.3 M | -454 K | -2.17 M | -7.31 M | -7.31 M | -2.17 M |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.6 K | - | - | - | - | - | - | - | - |
Operating Income |
-14.5 M | -12.5 M | -13.6 M | -17.2 M | -14.6 M | -12.6 M | -11.4 M | -13.6 M | - | -14.6 M | -12.6 M | -11.4 M | - | -13.5 M | -14.2 M | -15.4 M | - | -12.5 M | -11.5 M | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.51 M | -858 K | -771 K | -2.33 M | -999 K | -1.02 M | -310 K | -669 K | -126 K | -310 K | -416 K | -3.68 M | -698 K | -416 K | -2.19 M | -4.95 M | -1.64 M | -2.19 M |
Interest Expense |
1.08 M | 1.21 M | 1.39 M | 958 K | 1.8 M | 1.76 M | 2.01 M | 1.39 M | - | 1.8 M | 1.76 M | 2.01 M | - | 1.83 M | 1.46 M | 1.27 M | 242 K | 230 K | 7.58 K | 4.91 K | 19.1 K | 11.5 K | 9.22 K | -1.56 K | 173 K | 56.1 K | -1.56 K | 46.7 K | 165 K | 34.8 K | 46.7 K | 78.8 K | 171 K | 112 K | 78.8 K | 30.4 K | 48.5 K | 26.7 K | 30.4 K | 3.66 K | 6.83 K | 2.63 K | -2.06 K | -2.14 K | -73.5 K | 74.8 K | -2.23 K | 77 K | -16.9 K | 8.49 K | 77 K | 3.29 K | 41.6 K | 14.9 K | 3.29 K | 10.2 K | 130 K | 38 K | 10.2 K | 42.4 K | 15.9 K | 3.99 K | 42.4 K |
EBITDA |
-14.5 M | -12.5 M | -13.6 M | -17.2 M | -14.6 M | -12.6 M | -11.4 M | - | - | - | - | - | - | - | - | -15.4 M | - | -12.5 M | -11.5 M | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 746 | 497 | - | 249 | 746 | -1.51 M | -858 K | -770 K | -2.33 M | -998 K | -1.02 M | -309 K | -668 K | -126 K | -309 K | -415 K | -3.68 M | -697 K | -415 K | -2.19 M | -4.95 M | -1.64 M | -2.19 M |
Operating Expenses |
14.5 M | 12.5 M | 13.6 M | 17.2 M | 14.6 M | 12.6 M | 11.4 M | 13.6 M | - | 14.6 M | 12.6 M | 11.4 M | - | 13.5 M | 14.2 M | 15.4 M | 35.7 M | 12.5 M | 11.5 M | 11.7 M | 29.7 M | 11.4 M | 8.95 M | 9.4 M | 23.6 M | 8.11 M | 9.4 M | 7.7 M | 22.8 M | 7.15 M | 7.7 M | 7.47 M | 13.4 M | 4.62 M | 7.47 M | 4.09 M | 10.5 M | 3.71 M | 4.09 M | 3.17 M | 9.01 M | 2.29 M | 3.17 M | 4.53 M | 3.14 M | 1.51 M | 4.53 M | 771 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.5 M | 2.62 M | 3.15 M | 3.66 M | 2.79 M | 2.9 M | 2.69 M | 3.15 M | - | 2.79 M | 2.9 M | 2.69 M | - | 3.25 M | 2.88 M | 3.32 M | 9.17 M | 3.19 M | 2.92 M | 3.07 M | 6.14 M | 2.43 M | 2.23 M | 1.47 M | 4.45 M | 1.38 M | 1.47 M | 1.35 M | 5.21 M | 1.39 M | 1.35 M | 1.76 M | 4.51 M | 1.62 M | 1.76 M | 1.4 M | 3.65 M | 1.41 M | 1.4 M | 1.13 M | 5.12 M | 1.13 M | 1.13 M | 3.37 M | 1.62 M | 713 K | 451 K | 452 K | 1.94 M | 734 K | 903 K | 304 K | 502 K | 87 K | 2.31 K | - | 8.42 K | 2.96 K | - | 3.17 K | 24.6 K | 5 K | 3.17 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Main types of financial statements Anavex Life Sciences Corp. AVXLFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Anavex Life Sciences Corp. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Certara
CERT
|
$ 12.05 | 8.61 % | $ 1.93 B |  USA |
 |
Dyadic International
DYAI
|
$ 0.34 | -7.09 % | $ 12.3 M | USA |
 |
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M |  Israel |
 |
Anika Therapeutics
ANIK
|
$ 19.29 | -5.44 % | $ 277 M | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.5 | -1.96 % | $ 3.27 M | USA |
 |
Galectin Therapeutics
GALT
|
$ 2.98 | -14.12 % | $ 190 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 71.75 | -9.43 % | $ 7.45 B | USA |
 |
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
$ 2.09 | -2.34 % | $ 1.95 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
- | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.4 | -1.76 % | $ 125 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 56.14 | -1.74 % | $ 10.8 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.11 | -7.0 % | $ 6.08 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 10.06 | -5.54 % | $ 215 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.69 | -10.54 % | $ 73.3 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 88.15 | -8.29 % | $ 6.54 B | USA |
 |
Lipocine
LPCN
|
$ 1.52 | 5.56 % | $ 8.28 M | USA |
 |
Seres Therapeutics
MCRB
|
$ 2.09 | -2.63 % | $ 18.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 400.26 | -0.04 % | $ 8.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.35 | -2.88 % | $ 10.8 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.65 | -5.68 % | $ 218 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
$ 8.51 | -9.71 % | $ 684 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 47.29 | -6.76 % | $ 1.27 B | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 30.63 | -5.35 % | $ 2.71 B | USA |
 |
Lantern Pharma
LTRN
|
$ 0.55 | -5.33 % | $ 5.99 M | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 1.9 | -9.52 % | $ 120 M | USA |
 |
Minerva Neurosciences
NERV
|
$ 2.3 | -10.7 % | $ 19.5 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 6.89 | -7.14 % | $ 397 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
$ 159.9 | -3.7 % | $ 15.9 B | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 29.92 | 0.74 % | $ 1.43 T | France |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.28 | -7.49 % | $ 223 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 6.94 | -10.1 % | $ 1 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.61 | 8.78 % | $ 585 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.72 | 3.07 % | $ 10.3 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 14.83 | -7.02 % | $ 1.29 B | USA |
 |
Nkarta
NKTX
|
$ 1.59 | -8.38 % | $ 118 M | USA |
 |
MacroGenics
MGNX
|
$ 2.24 | -3.25 % | $ 141 M | USA |
 |
ImmuCell Corporation
ICCC
|
$ 9.88 | -4.77 % | $ 89.2 M | USA |
|
Nuvation Bio
NUVB
|
$ 4.19 | -11.42 % | $ 1.43 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.27 | -4.52 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.9 | -11.24 % | $ 13.8 M | USA |
 |
NextCure
NXTC
|
$ 5.16 | -12.39 % | $ 14.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 6.89 | -8.62 % | $ 599 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 124.88 | -8.34 % | $ 10.6 B | USA |
 |
Oragenics
OGEN
|
$ 0.34 | -9.47 % | $ 733 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.59 | -5.66 % | $ 337 M | USA |
 |
Passage Bio
PASG
|
$ 3.44 | -2.14 % | $ 11 M | USA |
 |
Vaxcyte
PCVX
|
$ 62.47 | -4.89 % | $ 8.5 B | USA |
 |
Precigen
PGEN
|
$ 4.2 | -16.94 % | $ 1.31 B | USA |